United Therapeutics Corp
NASDAQ:UTHR

Watchlist Manager
United Therapeutics Corp Logo
United Therapeutics Corp
NASDAQ:UTHR
Watchlist
Price: 284.27 USD 0.06% Market Closed
Market Cap: 12.8B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one UTHR stock under the Base Case scenario is 312.2 USD. Compared to the current market price of 284.27 USD, United Therapeutics Corp is Undervalued by 9%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

UTHR Relative Value
Base Case
312.2 USD
Undervaluation 9%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.3
P/S
P/S
Price to Sales
4.3
vs History
84
vs Industry
61
Median 3Y
5.3
Median 5Y
5.1
Industry
7.1
Forward
3.9
More Details
10.6
P/E
P/E
Price to Earnings
10.6
vs History
88
vs Industry
10
Median 3Y
13.2
Median 5Y
13.5
Industry
22.9
Forward
10.1
More Details
9.1
P/OCF
P/OCF
Price to OCF
9.1
vs History
84
vs Industry
13
Median 3Y
11.9
Median 5Y
11.9
Industry
19.4
More Details
18.2
P/FCFE
P/FCFE
Price to FCFE
18.2
vs History
34
vs Industry
9
Median 3Y
18.1
Median 5Y
17
Industry
22.6
More Details
1.9
P/B
P/B
Price to Book Value
1.9
vs History
77
vs Industry
39
Median 3Y
2.1
Median 5Y
2.2
Industry
2.7
More Details
3.2
EV/S
EV/S
Enterprise Value to Sales
3.2
vs History
88
vs Industry
57
Median 3Y
4.2
Median 5Y
4.3
Industry
7.4
Forward
2.9
More Details
3.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.6
vs History
87
vs Industry
59
Median 3Y
4.7
Median 5Y
4.7
Industry
9.2
More Details
6.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
6.4
vs History
90
vs Industry
12
Median 3Y
8.1
Median 5Y
8.3
Industry
4.5
Forward
5.6
More Details
6.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
6.8
vs History
90
vs Industry
11
Median 3Y
8.5
Median 5Y
8.8
Industry
4.5
Forward
6.4
More Details
6.7
EV/OCF
EV/OCF
Enterprise Value to OCF
6.7
vs History
92
vs Industry
14
Median 3Y
9.8
Median 5Y
9.8
Industry
5
More Details
8.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
8.4
vs History
84
vs Industry
10
Median 3Y
12.2
Median 5Y
12.2
Industry
3.7
More Details
2.3
EV/IC
EV/IC
Enterprise Value to IC
2.3
vs History
69
vs Industry
40
Median 3Y
2.7
Median 5Y
2.6
Industry
4.9
More Details

Multiples Across Competitors

UTHR Competitors Multiples
United Therapeutics Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
United Therapeutics Corp
NASDAQ:UTHR
12.8B USD 4.3 10.6 6.4 6.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 936 878.5 -161 297 -195 865.9 -193 630.9
US
Abbvie Inc
NYSE:ABBV
322B USD 5.6 77.5 14.8 21.9
US
Amgen Inc
NASDAQ:AMGN
149B USD 4.4 25.1 13.7 22.6
US
Gilead Sciences Inc
NASDAQ:GILD
137.8B USD 4.8 23.1 10 13.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.4B USD 10.2 -114.7 24.3 25.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 075.9 -529.7 -576.8 -561.4
AU
CSL Ltd
ASX:CSL
113.5B AUD 4.9 27 16.7 20.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
56.4B USD 4 12.5 11.1 12.5
US
Seagen Inc
F:SGT
39.3B EUR 20 -61.3 -66.1 -59.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
42.1B USD 17.9 -156 -699.8 -350.7
P/E Multiple
Earnings Growth PEG
US
United Therapeutics Corp
NASDAQ:UTHR
Average P/E: 29.3
10.6
3%
3.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 297 N/A N/A
US
Abbvie Inc
NYSE:ABBV
77.5
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.1
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -114.7 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -529.7 N/A N/A
AU
CSL Ltd
ASX:CSL
27
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -156 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
United Therapeutics Corp
NASDAQ:UTHR
Average EV/EBITDA: 13.9
6.4
2%
3.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 865.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.8
13%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.7
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.3
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -576.8 N/A N/A
AU
CSL Ltd
ASX:CSL
16.7
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.1
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -699.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
United Therapeutics Corp
NASDAQ:UTHR
Average EV/EBIT: 17.7
6.8
6%
1.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 630.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
21.9
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.6
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.9
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.4 N/A N/A
AU
CSL Ltd
ASX:CSL
20.9
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -350.7 N/A N/A

See Also

Summary
UTHR intrinsic value, competitors valuation, and company profile.
DCF Valuation
UTHR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
UTHR stock valuation using valuation multiples.
Wall Street Estimates
UTHR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
UTHR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 264,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.